ArticleJournal of health, population, and nutrition2026
Association between metabolic dysregulation and frailty in four prospective cohorts.
Article in Journal of health, population, and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cross-lag association between TyG-CVAI and frailty index: evidence from a natural population cohort in southwestern China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe relationship between metabolic dysregulation and frailty remains incompletely understood. This study examines the association between metabolic dysregulation and frailty in middle-aged and older adults.
methodsData from four cohorts (CHARLS, HRS, SHARE, MHAS) were analysed. Frailty was assessed using a 30-item deficit accumulation frailty index, treated as a continuous variable ranging from 0-100. Metabolic dysregulation was defined based on the presence of central obesity, high blood pressure, and/or hyperglycaemia, and was analysed both as a categorical count variable (0, 1, 2, or 3 dysregulations) and as specific combinations of individual metabolic components. Multivariable linear regression models were used to examine associations, adjusting for demographic, lifestyle, and clinical factors.
resultsAmong 416,693 participants, 63.7% had at least one metabolic dysregulation. A dose-response pattern was observed: β-values for frailty were 4.31 (95% CI: 4.22-4.40) for one dysregulation, 8.36 (95% CI: 8.24-8.49) for two, and 12.92 (95% CI: 12.79-13.16) for three. Hyperglycemia had the strongest effect, especially when combined with high blood pressure, and remained significant after adjustment.
conclusionMetabolic dysregulation synergistically accelerates frailty progression, underscoring the need for early intervention in metabolic disorders to prevent frailty.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.